PT  - JOURNAL ARTICLE
AU  - Sanjoyita Mallick
AU  - Gautam R. Shroff
AU  - Mark Linzer
TI  - Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say?
AID  - 10.3949/ccjm.90a.22087
DP  - 2023 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 287--291
VI  - 90
IP  - 5
4099  - http://www.ccjm.org/content/90/5/287.short
4100  - http://www.ccjm.org/content/90/5/287.full
SO  - Cleve Clin J Med2023 May 01; 90
AB  - The 2022 US Preventive Services Task Force (USPSTF) recommendation notes that the decision to initiate daily aspirin therapy for primary prevention of cardiovascular disease (CVD) should be made on a case-by-case basis for adults ages 40 to 59 with a 10% or greater 10-year CVD risk. The recommendation applies to those without signs or symptoms of clinically evident CVD who are not at an increased risk of bleeding. Clinicians are encouraged to use their judgment in weighing the risks and benefits of aspirin therapy, while taking patient preference into account for patients ages 40 to 60.